These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 36948674)
61. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042 [TBL] [Abstract][Full Text] [Related]
62. Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC). Harshman LC; Yu RJ; Allen GI; Srinivas S; Gill HS; Chung BI Urol Oncol; 2013 Apr; 31(3):379-85. PubMed ID: 21353796 [TBL] [Abstract][Full Text] [Related]
63. Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Non-clear Cell Renal Cell Carcinoma Patients. Luzzago S; Palumbo C; Rosiello G; Knipper S; Pecoraro A; Mistretta FA; Tian Z; Musi G; Montanari E; Soulières D; Shariat SF; Saad F; Briganti A; de Cobelli O; Karakiewicz PI Eur Urol Focus; 2021 May; 7(3):598-607. PubMed ID: 32444303 [TBL] [Abstract][Full Text] [Related]
64. Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma. Hsiang WR; Kenney PA; Leapman MS Curr Oncol Rep; 2020 Mar; 22(4):35. PubMed ID: 32170461 [TBL] [Abstract][Full Text] [Related]
66. Cytoreductive nephrectomy in metastatic kidney cancer: what do we do now? Kokorovic A; Rendon RA Curr Opin Support Palliat Care; 2019 Sep; 13(3):255-261. PubMed ID: 31082942 [TBL] [Abstract][Full Text] [Related]
67. The use of cytoreductive nephrectomy in patients with renal cell carcinoma. Ghandour RA; Singla N; Margulis V Expert Rev Anticancer Ther; 2019 May; 19(5):405-411. PubMed ID: 31020871 [TBL] [Abstract][Full Text] [Related]
69. [A case of metastatic renal cell carcinoma with no evidence of disease for a long term after a favorable response to molecular-targeted therapy followed by metastasectomy]. Ikehata Y; Takahashi S; Kitamura H; Masumori N; Tsukamoto T Hinyokika Kiyo; 2013 Jun; 59(6):369-72. PubMed ID: 23827870 [TBL] [Abstract][Full Text] [Related]
70. Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy? Pantuck AJ; Belldegrun AS; Figlin RA Clin Cancer Res; 2007 Jan; 13(2 Pt 2):693s-696s. PubMed ID: 17255295 [TBL] [Abstract][Full Text] [Related]
71. Surgical and focal treatment for metastatic renal cell carcinoma: A literature review. Naito S; Kato T; Tsuchiya N Int J Urol; 2022 Jun; 29(6):494-501. PubMed ID: 35340081 [TBL] [Abstract][Full Text] [Related]
72. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Wood CG Clin Cancer Res; 2007 Jan; 13(2 Pt 2):697s-702s. PubMed ID: 17255296 [TBL] [Abstract][Full Text] [Related]
73. Delayed surgery for localised and metastatic renal cell carcinoma: a systematic review and meta-analysis for the COVID-19 pandemic. Chan VW; Tan WS; Leow JJ; Tan WP; Ong WLK; Chiu PK; Gurung P; Pirola GM; Orecchia L; Liew MPC; Lee HY; Wang Y; Chen IA; Castellani D; Wroclawski ML; Mayor N; Sathianathen NJ; Braga I; Liu Z; Moon D; Tikkinen K; Kamat A; Meng M; Ficarra V; Giannarini G; Teoh JY World J Urol; 2021 Dec; 39(12):4295-4303. PubMed ID: 34031748 [TBL] [Abstract][Full Text] [Related]
74. The operative safety and oncological outcomes of laparoscopic nephrectomy for T3 renal cell cancer. Stewart GD; Ang WJ; Laird A; Tolley DA; Riddick AC; McNeill SA BJU Int; 2012 Sep; 110(6):884-90. PubMed ID: 22289017 [TBL] [Abstract][Full Text] [Related]
75. Combination of surgery and immunotherapy in metastatic renal cell carcinoma. Mickisch GH; Mattes RH World J Urol; 2005 Jul; 23(3):191-5. PubMed ID: 15791469 [TBL] [Abstract][Full Text] [Related]
77. Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomy. Russo P; O'Brien MF Urol Clin North Am; 2008 Nov; 35(4):679-86; viii. PubMed ID: 18992621 [TBL] [Abstract][Full Text] [Related]
78. TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery. Verzoni E; Ratta R; Grassi P; Salvioni R; Stagni S; Montone R; Fucà G; Cappelletti V; Reduzzi C; De Giorgi U; Procopio G Tumori; 2018 Oct; 104(5):401-405. PubMed ID: 29192741 [TBL] [Abstract][Full Text] [Related]
79. Cytoreductive nephrectomy: does CARMENA (Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques) change everything? Grant M; Szabados B; Kuusk T; Powles T; Bex A Curr Opin Urol; 2020 Jan; 30(1):36-40. PubMed ID: 31789991 [TBL] [Abstract][Full Text] [Related]
80. Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Abel EJ; Wood CG Nat Rev Urol; 2009 Jul; 6(7):375-83. PubMed ID: 19528960 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]